Welcome to our dedicated page for Dermata Therapeutics SEC filings (Ticker: DRMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dermata Therapeutics, Inc. (DRMA) SEC filings page on Stock Titan aggregates the company’s official U.S. regulatory disclosures, offering a structured view of how this dermatology-focused biotechnology issuer reports its activities. Dermata uses SEC filings to describe progress with its Spongilla technology platform, clinical programs such as XYNGARI™ and DMT410, financing arrangements, and key corporate decisions.
Current and prospective investors can review Form 8-K filings for material events, including press release disclosures about clinical trial data, strategic pivots, financing transactions, and significant agreements. For example, Dermata has filed 8-Ks discussing its corporate updates and financial results, the presentation of Phase 3 STAR-1 acne data, increases to its at-the-market offering capacity, and the termination of a License Agreement with Villani, Inc. related to sponge-based pharmaceutical products.
Annual Form 10-K and quarterly Form 10-Q reports (when available) provide more comprehensive information on Dermata’s business, risk factors, financial statements, and details on its lead programs XYNGARI™ and DMT410. These filings also reference key licensing arrangements, intellectual property, and the company’s shift toward over-the-counter pharmaceutical dermatology products.
On Stock Titan, Dermata’s filings are complemented by AI-powered summaries designed to clarify complex sections of lengthy documents, such as clinical trial descriptions, capital structure changes, and agreement terms. Users can quickly understand the implications of new 8-Ks, 10-Qs, and 10-Ks without reading every page, while still having direct access to the full text filed with the SEC. This page also surfaces information relevant to equity offerings and at-the-market programs, helping readers follow how Dermata funds its dermatology pipeline and OTC initiatives.
Dermata Therapeutics reported new clinical data from its Phase 3 STAR-1 trial of XYNGARI™ (DMT310) for acne, presented in an abstract at the 2025 European Academy of Dermatology and Venereology Congress. In an intent-to-treat analysis, XYNGARI showed statistically significant improvements versus placebo in multiple measures, including Investigator Global Assessment (IGA) treatment success, inflammatory lesion counts, and non-inflammatory lesion counts at weeks 4, 8, and 12.
For IGA treatment success defined as a 2-point reduction and a score of 0 or 1, XYNGARI achieved 29.4% of patients at week 12 compared with 15.2% on placebo. XYNGARI also had greater mean and percent reductions from baseline in both inflammatory and non-inflammatory lesion counts across all time points, supporting a consistent efficacy benefit over placebo in this Phase 3 acne study.